SG Americas Securities LLC Buys 15,203 Shares of Exelixis, Inc. $EXEL

SG Americas Securities LLC boosted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 72.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,288 shares of the biotechnology company’s stock after purchasing an additional 15,203 shares during the quarter. SG Americas Securities LLC’s holdings in Exelixis were worth $1,591,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in EXEL. Richardson Financial Services Inc. increased its holdings in shares of Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares during the last quarter. Cim LLC boosted its stake in Exelixis by 0.9% during the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after buying an additional 305 shares during the last quarter. Evergreen Capital Management LLC grew its holdings in Exelixis by 6.4% during the 3rd quarter. Evergreen Capital Management LLC now owns 5,450 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Exelixis by 5.1% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock valued at $327,000 after buying an additional 384 shares in the last quarter. Finally, North Star Asset Management Inc. increased its stake in Exelixis by 0.7% in the 3rd quarter. North Star Asset Management Inc. now owns 57,550 shares of the biotechnology company’s stock worth $2,377,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on EXEL shares. HC Wainwright upped their price objective on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Stifel Nicolaus boosted their price target on shares of Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target on the stock. in a research note on Monday, January 5th. UBS Group set a $41.00 price objective on shares of Exelixis in a research report on Monday, January 5th. Finally, Morgan Stanley lifted their price objective on shares of Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $46.94.

Insiders Place Their Bets

In related news, EVP Dana Aftab sold 47,918 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the transaction, the executive vice president directly owned 616,106 shares in the company, valued at approximately $27,416,717. This represents a 7.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 67,814 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the completion of the sale, the executive vice president directly owned 381,908 shares in the company, valued at $16,620,636.16. This trade represents a 15.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 362,849 shares of company stock valued at $15,917,463. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Performance

Shares of Exelixis stock opened at $43.98 on Tuesday. The stock has a market cap of $11.42 billion, a price-to-earnings ratio of 15.88, a price-to-earnings-growth ratio of 0.98 and a beta of 0.42. The stock has a 50 day moving average price of $42.69 and a 200-day moving average price of $42.16. Exelixis, Inc. has a one year low of $32.38 and a one year high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.Exelixis’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 EPS. Sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.